Genetic Disease Clinical Trial
— ORIGINOfficial title:
Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN
Next generation sequencing (NGS) allows some better diagnostic results, particularly, in the rare diseases field. At a twenty five percent rate, those exams highlight some variants which are not yet described in human pathology. The relationship between a variant found inside a candidate gene and a pathology, is able to be confirmed by functional studies at a protein level. This study aims to build a biological collection to feed further functional studies to confirm the relationship between NGS identified variants, and the clinical signs and symptoms.
Status | Recruiting |
Enrollment | 1200 |
Est. completion date | October 10, 2045 |
Est. primary completion date | October 10, 2042 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: Patient : - Child or adult affected by a rare disease whose molecular functions are not known, or whose pathophysiologic mechanism are not fully understood. - Patient included inside the BaMaRa (French rare disease national data bank) database dedicated to the rare diseases. - Patient Affiliated to the French social security system. - Patient consent form or legal representative consent form obtained. Patient's parent : - Parent of a patient affected by a rare disease whose molecular functions are not known, or whose pathophysiologic mechanism are not fully understood. - Parent included in the BaMaRa database. - Parent affiliated to the French social security system. - Parent consent form obtained for himself/herself. Patient's brother or sister : - Brother or sister of a patient (underage or adult) affected by a rare disease whose molecular functions are not known, or whose pathophysiologic mechanism are not fully understood. - Brother or sister included in the BaMaRa database. - Brother or sister affiliated to the French social security system. - Brother or sister consent form obtained for themselves or from their legal representative. Exclusion Criteria: - Poor understanding of the French language - Legal of administrative liberty deprivation - Psychiatric force care |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalo-Universitaire d'Angers | Angers |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Angers |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identification of at least 80 new genes implicated in rare diseases via high-throughput sequencing technics and through functional studies. | Candidate genes, suspected to be responsible for rare diseases will be identified before the inclusion, during standard medical care, by exome or genome sequencing. | 23 years | |
Primary | Collecting biological samples to build up a biobank | After a candidat gene identification, patient will be proposed sampling (blood or urine) or if a skin biopsy, an amniotic fluid puncture or any surgery are done during standard care, the remaing tissue or fluid, or operative wastes will be eligible too, to be stored in the biobank. | 23 years | |
Primary | Candidat gene validation through functional studies. | Biological samples from the biobank will be made available after the study, to some specialized research teams, in order to validate or overturn those previously gene candidates by the way of some biological technics. | 23 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03548779 -
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
|
N/A | |
Completed |
NCT03292302 -
Phase 1 Study of ELX-02 in Healthy Adults
|
Phase 1 | |
Withdrawn |
NCT03658382 -
Virtual Visits for Results Disclosure
|
N/A | |
Recruiting |
NCT02266615 -
Biobank Clinical Genetics Maastricht (KG01)
|
||
Recruiting |
NCT02450851 -
Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
|
||
Recruiting |
NCT05472714 -
Educational Video for Genetic Testing
|
N/A | |
Recruiting |
NCT04285814 -
Technology Development for Noninvasive Prenatal Genetic Diagnosis Using Whole Fetal Cells From Maternal Peripheral Blood
|
||
Completed |
NCT05443113 -
Young Pectus Excavatum Patients and Genetic Defects
|
||
Completed |
NCT05655741 -
Modified Delphi for Genomic Bereavement Care
|
||
Completed |
NCT03847909 -
A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2
|
Phase 2 | |
Completed |
NCT04584528 -
Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease
|
N/A | |
Not yet recruiting |
NCT06048523 -
Prospective Cohort Study of Neurogenetic Diseases
|
N/A | |
Completed |
NCT02225522 -
Genomic Sequencing in Acutely Ill Neonates
|
N/A | |
Enrolling by invitation |
NCT06089954 -
Penn Medicine Biobank Return of Results Program
|
N/A | |
Completed |
NCT03713333 -
Implementing Digital Health in a Learning Health System
|
N/A | |
Completed |
NCT03309605 -
Phase 1 Study of ELX-02 in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT04556500 -
Turkish Version of the Affordance in the Home Environment for Motor Development-Toddler (AHEMD-T)
|
||
Completed |
NCT04556487 -
Turkish Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)
|
||
Recruiting |
NCT02551081 -
Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units
|
||
Active, not recruiting |
NCT05049967 -
iKnow: A Prospective Study to Evaluate the Use of Multi-omics in Multi-System, Early Onset Disorders
|